Analyzing...
Loading company...
Akums Drugs & Pharmaceuticals Ltd manufactures and distributes pharmaceutical products including injectables, generics, and hospital supplies. The company ensures high-quality standards and regulatory compliance.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,359 Cr revenue.
COGS 57.7%, employees 17.3%.
“CDMO margins fell so sharply.”
“So '26, we'll have $25 million of revenue in the calendar year '26 coming in, and then similarly, in calendar year '27 as well, we'll have $25 million of revenue coming in the CDMO.”
“EBITDA margins.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 7.7%▼ | 10.3% |
| ROCE | 10.9%▼ | 13.7% |
| Net Margin | 5.7%▼ | 7.6% |
| EBITDA Margin | 14.1%▼ | 15.4% |
| Debt To Equity | 0.02x▼ | 0.15x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹4,359 Cr +5.8% | ₹4,118 Cr |
| Other Income | ₹129 Cr +147.0% | ₹52 Cr |
| Total Income | ₹4,488 Cr +7.6% | ₹4,170 Cr |
| COGS | ₹2,514 Cr +3.3% | ₹2,433 Cr |
| ₹4,086 Cr +6.3% | ₹3,842 Cr | |
| Profit Before Tax | ₹382 Cr +10.7% | ₹345 Cr |
| Exceptional Items | (₹20 Cr) ↓ Decline | ₹17 Cr |
| ₹126 Cr | ₹1 Cr | |
| Net Profit | ₹256 Cr -25.4% | ₹344 Cr |
| Profit (Owners) | ₹255 Cr -24.5% | ₹338 Cr |
| Minority Interest | ₹1 Cr -78.4% | ₹6 Cr |
| Other Comprehensive Income | ₹0.92 Cr ↑ Recovery | (₹1 Cr) |
| EPS | ₹16.21 | ₹21.49 |
| Diluted Shares | ₹16 Cr | ₹16 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of Oriflame India s Manufacturing business
Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 10, 2026. Further, the company has informed the Exchange regarding ...
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 10, 2026
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Newspaper Advertisements of the 22nd Annual General Meeting of the Company
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Notice and Integrated Annual Report for the Financial Year 2025-26 to those members who have not registered their e-mail ID...
Newspaper Advertisement- Information regarding 22nd AGM and Final & Special Dividend
Intimation of Schedule of the investor/analysts meets
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department
Transcript of Investors/Analysts Conference Call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26
Link of Audio Recording of Investor/Analysts Conference Call
Update on Disruption of Operations
Update on Disruption in Operations at some of the manufacturing sites at Haridwar
Intimation regarding Newspaper Publication